PE20081580A1 - Composicion suplementaria nutricional para el tratamiento enfermedades oculares - Google Patents

Composicion suplementaria nutricional para el tratamiento enfermedades oculares

Info

Publication number
PE20081580A1
PE20081580A1 PE2007001783A PE2007001783A PE20081580A1 PE 20081580 A1 PE20081580 A1 PE 20081580A1 PE 2007001783 A PE2007001783 A PE 2007001783A PE 2007001783 A PE2007001783 A PE 2007001783A PE 20081580 A1 PE20081580 A1 PE 20081580A1
Authority
PE
Peru
Prior art keywords
nutritional composition
treatment
eye diseases
vitamin
supplementary nutritional
Prior art date
Application number
PE2007001783A
Other languages
English (en)
Inventor
Georg Ludwig Kis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024441&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081580(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081580A1 publication Critical patent/PE20081580A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE REFIERE A UNA COMPOSICION SUPLEMENTARIA NUTRICIONAL QUE COMPRENDE EN UNA BASE DE DOSIS DIARIA: VITAMINA C DE 40 A 80 MG; VITAMINA E DE 15 A 25 MG; LUTEINA DE 7 A 14 MG; ZINC DE 8 A 15 MG; ACIDO GRASO OMEGA-3 DE 100 A 300 MG SIENDO SELECCIONADO EL ACIDO DOCOHEXANOICO Y EICOSAPENTANOICO; OPCIONALMENTE ALREDEDOR DE 0,1 A 0,3 MG DE COBRE, ADEMAS COMPRENDE ZEAXANTINA DE 100 A 2000 MICROGRAMOS, PRESENTANDOSE BAJO FORMA DE TABLETA, CAPSULA O PELLA. ESTA COMPOSICION REDUCE LA PERDIDA DE AGUDEZ VISUAL REDUCIENDO EL RIESGO DE DESARROLLAR DEGENERACION MACULAR DE ETAPA TARDIA O RELACIONADA CON LA EDAD Y/O RETINOPATIA DIABETICA
PE2007001783A 2006-12-15 2007-12-13 Composicion suplementaria nutricional para el tratamiento enfermedades oculares PE20081580A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06126261A EP1932521A1 (en) 2006-12-15 2006-12-15 Nutritional supplement composition for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
PE20081580A1 true PE20081580A1 (es) 2009-01-01

Family

ID=38024441

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001783A PE20081580A1 (es) 2006-12-15 2007-12-13 Composicion suplementaria nutricional para el tratamiento enfermedades oculares

Country Status (22)

Country Link
US (1) US20100028459A1 (es)
EP (2) EP1932521A1 (es)
JP (1) JP2010513248A (es)
KR (1) KR20090089473A (es)
CN (1) CN101557807A (es)
AR (1) AR064332A1 (es)
AU (1) AU2007331432A1 (es)
BR (1) BRPI0720046A2 (es)
CA (1) CA2672013A1 (es)
CL (1) CL2007003630A1 (es)
CO (1) CO6220929A2 (es)
EC (1) ECSP099516A (es)
GT (1) GT200900161A (es)
MA (1) MA30994B1 (es)
MX (1) MX2009006306A (es)
NO (1) NO20092633L (es)
PE (1) PE20081580A1 (es)
RU (1) RU2009126735A (es)
TN (1) TN2009000241A1 (es)
TW (1) TW200843725A (es)
WO (1) WO2008071775A1 (es)
ZA (1) ZA200903862B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389504B2 (en) * 2008-05-08 2013-03-05 Mead Johnson Nutrition Company Prenatal dietary supplement
WO2010074940A1 (en) * 2008-12-23 2010-07-01 Alcon Research, Ltd. Compositions and nutritional supplements for improving ocular health and reducing ocular inflammatory response
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US20130011469A1 (en) 2009-07-23 2013-01-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Krill oil and carotenoid composition, associated method and delivery system
US20110237548A1 (en) * 2009-07-23 2011-09-29 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
CN103796717A (zh) * 2011-07-07 2014-05-14 霍华德基金会控股有限公司 视觉功效和/或黄斑色素沉着的改善或与之相关的改善
US9115078B2 (en) 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
US9381183B2 (en) 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
JP2016508955A (ja) * 2011-09-12 2016-03-24 ジョルジオ タソスＧＥＯＲＧＩＯＵ， Ｔａｓｓｏｓ 疾病治療用オメガ脂肪酸の使用
CN102538980A (zh) * 2012-01-12 2012-07-04 杭州美盛红外光电技术有限公司 热像装置和热像拍摄方法
JP2016185939A (ja) * 2015-03-27 2016-10-27 ロート製薬株式会社 経口組成物
JP2016190829A (ja) * 2015-03-31 2016-11-10 ウィルファーム株式会社 活性型ｄｈａを含む製剤、強化食品、サプリメント並びに化粧品
JP6056114B2 (ja) * 2015-05-30 2017-01-11 富田製薬株式会社 油状物質含有粉末組成物
CN108208804A (zh) * 2018-01-05 2018-06-29 美博迪尔（北京）生物科技有限公司 一种缓解眼睛干涩、抵御蓝光损伤及保护眼底的组合物及其制备方法
CN108096288A (zh) * 2018-01-16 2018-06-01 南京圣诺生物科技实业有限公司 护眼片及其制备方法和应用
EP4117652A1 (en) * 2020-03-11 2023-01-18 Bausch + Lomb Ireland Limited Compositions and methods for eye health comprising very long chain fatty acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
US20050112210A1 (en) * 2003-09-12 2005-05-26 Terry Grossman Eye nutritional supplement
WO2005110375A1 (en) * 2004-05-08 2005-11-24 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
DE202005012984U1 (de) * 2005-08-17 2005-11-24 W & B Pharmamarken Gmbh Arzneimittel- und Nahrungsergänzungsmittelkombinationen zur Behandlung von Augenerkrankungen
EP1962618A2 (en) * 2005-12-20 2008-09-03 Alcon Research, Ltd. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision

Also Published As

Publication number Publication date
MA30994B1 (fr) 2009-12-01
TN2009000241A1 (en) 2010-10-18
TW200843725A (en) 2008-11-16
BRPI0720046A2 (pt) 2013-12-24
EP2094252A1 (en) 2009-09-02
CA2672013A1 (en) 2008-06-19
JP2010513248A (ja) 2010-04-30
MX2009006306A (es) 2009-06-23
CN101557807A (zh) 2009-10-14
EP1932521A1 (en) 2008-06-18
ECSP099516A (es) 2009-08-28
RU2009126735A (ru) 2011-01-20
CL2007003630A1 (es) 2008-08-08
CO6220929A2 (es) 2010-11-19
ZA200903862B (en) 2010-05-26
KR20090089473A (ko) 2009-08-21
WO2008071775A1 (en) 2008-06-19
GT200900161A (es) 2009-11-30
AR064332A1 (es) 2009-04-01
US20100028459A1 (en) 2010-02-04
NO20092633L (no) 2009-07-10
AU2007331432A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
PE20081580A1 (es) Composicion suplementaria nutricional para el tratamiento enfermedades oculares
Study et al. Lutein+ zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
WO2005110375A8 (en) Nutritional supplement for treatment of ocular diseases
AR074861A1 (es) Composiciones y suplementos nutricionales para mejorar la salud ocular y reducir la respuesta inflamatoria ocular
BR0208640A (pt) Suplemento nutricional para tratar degeneração macular
US20130224281A1 (en) Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
NZ600167A (en) Concentrated therapeutic phospholipid compositions
GB201014340D0 (en) Nutritional supplement formulation comprising saffron and resveratrol
RU2009126740A (ru) Композиция питательной добавки, предназначенная для лечения глазных болезней
WO2009111603A3 (en) Deitary supplement for eye health
DOP2006000208A (es) Suplementos nutricionales con fitosterol
MX2018014083A (es) Composiciones nutritivas para la proteccion cardiaca en animales de compañia.
JP2014504605A5 (es)
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
SG162836A1 (en) Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
JP2015007092A (ja) 大量の栄養補給剤の負の副作用なしに、環境ストレスの作用に対抗し、免疫を改善し、活動力を改善し、一方でビタミンおよび無機質の欠乏に対処するための、マルチビタミン／無機質配合物
GB2585619A (en) A supplement
NZ761512A (en) Prevention and/or treatment of neurodegenerative disease
AR070405A1 (es) Composiciones para la prevencion y/o el tratamiento de la degeneracion macular y/o la perdida de la agudeza visual
TW201511766A (zh) 用於增進男性性健康之方法及組合物
US11116246B2 (en) Compositions of coenzyme Q10 and methods of use
WO2012025229A8 (en) Composition and method of manufacture
Fiorini et al. Can you hear me now? The quest for better guidance on omega-3 fatty acid consumption to combat hearing loss
Trinidad et al. Importance of the Nutrition with Antioxidants in the Treatment of Cancer and Others Damages
Buitendijk et al. Trace elements, vitamins, and lipids and age-related macular degeneration: an overview of the current concepts on nutrients and AMD

Legal Events

Date Code Title Description
FD Application declared void or lapsed